FILE - A sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017. A closely watched Alzheimer's drug from Eli Lilly won the backing of federal health advisers on Monday, June 10, 2024, setting the stage for the treatment's expected approval for people with mild dementia caused by the brain-robbing disease. (AP Photo/Darron Cummings, File)



A highly anticipated Alzheimer's medication by Eli Lilly received approval from federal health advisors on Monday, paving the way for its expected clearance to treat mild dementia caused by the disease. 

The drug, donanemab, demonstrated the potential to slow down the progression of Alzheimer's, with FDA advisors unanimously agreeing that its benefits outweighed its risks, including side effects like brain swelling and bleeding. Panel member Dean Follmann, a statistician from the National Institutes of Health, expressed confidence in the drug's effectiveness based on trial evidence.

 The FDA will have the final say on its approval later this year, and if greenlit, donanemab would be only the second Alzheimer's drug in the U.S. proven to effectively slow cognitive decline and memory loss caused by the disease. The FDA previously approved a similar infused drug, Leqembi, from Eisai in 2023. While both medications demonstrated a modest delay in cognitive decline among patients with early-stage Alzheimer's, there were questions raised regarding Lilly's approach to studying donanemab.

 Lilly's use of tau protein levels to group patients led to concerns about whether tau screening via brain scans would be necessary before administering the drug. However, most panelists concluded that there was sufficient evidence of the drug's benefits to warrant broader prescription without such screening. 

Additionally, Lilly's strategy of discontinuing treatment for patients with low levels of amyloid, a key contributor to Alzheimer's, was met with some skepticism from FDA staff due to insufficient data supporting the optimal timing for stopping treatment. Nonetheless, many panelists saw potential benefits in this approach, citing potential cost savings and reduced side effects. 

The main safety concern associated with donanemab was brain swelling and bleeding, although most cases observed during Lilly's trial were mild. The panel agreed that these risks could be managed through warning labels, physician education, and medical scans to identify patients at higher risk of stroke. Despite the uncertainties surrounding Lilly's testing methods, the FDA panel's endorsement marks a significant step forward in the development of Alzheimer's treatments.

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

You may also like

Kennedy’s HHS Overhaul Puts Addiction Treatment At Risk

A major shakeup in the U.S. Department of Health and Human Services (HHS) could lead to the weakening—or even elimination—of....

Deadly Fungal Superbug Candida Auris Spreads Rapidly in Hospitals

A dangerous fungal superbug, Candida auris (C. auris), is rapidly spreading in hospitals and nursing homes, raising serious public health....

Researchers in Limbo as Columbia Caves to Trump’s Demands for $400M

Columbia University is facing intense scrutiny after agreeing to strict policy changes to regain $400 million in federal funding revoked....

U.S. Cuts LGBTQ Health Research Funding, Sparking Outrage

The Trump administration has abruptly canceled dozens of federal grants supporting research on LGBTQ health, drawing criticism from scientists and....

Canada Expands Dental Care Plan Ahead of Expected Election

Millions of uninsured Canadians will soon have access to affordable dental care as the federal government expands its Canadian Dental....

Diffabilities YEG Fights Stigma On World Down Syndrome Day

An Edmonton-based organization, Diffabilities YEG, hosted a special event on Friday to mark World Down Syndrome Day. The event aimed....

Bella Ramsey Opens Up About Autism Diagnosis: "It Was Liberating"

Bella Ramsey, known for their Emmy-nominated role in The Last of Us, recently revealed their autism diagnosis. In an interview....

Measles Cases Double in Alberta as Vaccination Rates Decline

Measles, once considered eradicated in Canada, is making a troubling comeback in Alberta. The number of confirmed cases has nearly....

Slushy Drinks Could Make Kids Sick—Experts Warn!

Researchers have warned that children under the age of 8 should avoid slushy ice drinks containing glycerol. This comes after....

Alberta Government Lawyers Defend Youth Gender-Affirming Care Ban In Court

Alberta's controversial transgender law returned to court on Tuesday, with government lawyers defending it as a science-based measure designed to....

Utah Becomes First U.S. State to Ban Fluoride in Public Water

Utah is making history by becoming the first state to ban fluoride in public drinking water. Despite opposition from dentists....

Butter Lovers, Beware! New Study Links Butter Intake to Shorter Lifespan

Butter is a kitchen staple, loved for its creamy richness. But could your daily dollop be shortening your life? A....